Synthesis and evaluation of some new 2-(5-(4-benzamidobenzylidene)-2,4-dioxothiazolidin-3-yl)acetic acid analogs as aldose reductase inhibitors

Abstract

Objective: Aldose reductase (ALR) enzyme plays a significant role in conversion of excess amount of glucose into sorbitol in diabetic condition, inhibitors of which decrease the secondary complication of diabetes mellitus. Scarce treatment of diabetic complications has motivated our interest for the search of new aldose reductase inhibitors (ARIs) endowed with more favorable biological properties. Methods: Newer (4-(benzamidobenzylidene)-2,4-dioxothiazolidin-3-yl) acetic acid derivatives were synthesized, and these compound were evaluated for their ARI and antidiabetic activity. Results: ARI activity of synthesized compounds was found in the range of 57.8-71.9% at 5µg/mL. Similarly, synthesized compounds decrease blood glucose level in the range of 64.4-70.5 mg/dl at 15 mg/kg body weight. Conclusion: (E)-2-(5-(4-(substituted benzamido)benzylidene)-2,4-dioxothiazolidin-3-yl)acetic acid analogs shows comparable ARI as well as antidiabetic activity. These new class of compounds might be address the diabetic complications with safety.